Reactions 1680, p106 - 2 Dec 2017 Vitreous haemorrhage and hypokalaemia: 2 case report In a retrospective observational study of 46 patients, two patients [ages and sexes not stated] were described, who developed vitreous haemorrhage (one patient) and hypokalaemia (one patient) during treatment with etoposide and cytarabine [duration of treatments to reaction onsets and outcomes not stated]. The patients, who had a history of lymphoma, were scheduled to undergo peripheral blood stem cell harvest. The stem cell mobilisation was carried out with continuous infusion of etoposide 100 mg/m /day and continuous infusion of cytarabine 100 mg/m /day, both were administered from day one to day four. However, one patient developed grade III vitreous haemorrhage and one patient developed grade III hypokalaemia. Author comment: "Only two patients developed grade 3 non-hematological adverse events (one vitreous hemorrhage and one hypokalemia). . .Other non-hematological severe adverse events were rarely observed; therefore, the toxicity of the EC regimen was acceptable on the whole." Koyama D, et al. Effective chemomobilization with etoposide and cytarabine (EC regimen) in lymphoma patients: A single-center, retrospective, observational study. Japanese Journal of Clinical Oncology 47: 820-825, No. 9, Sep 2017. Available from: URL: http://doi.org/10.1093/jjco/hyx076 - Japan 803284128 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera